Lung Cancer Detection Using Deep Learning

Lung cancer is one of the leading causes of death worldwide, and its early diagnosis is crucial to improving patients prognosis and quality of life. However, the process of interpreting medical images for the detection of lung cancer is complex and requires trained experts. In this context, artificial intelligence (AI) and deep learning (DL) emerge as potential tools to automate and optimize image analysis. The objective of this work is to review the most recent and relevant applications of AI and DL in the field of radiology for the detection of lung cancer. To this end, an exhaustive search was carried out in scientific databases such as PubMed,IEEEXPLORE, Scopus and Web of Science, and 96 articles published from 2015 to the present addressing the use of AI and DL in biomedical engineering were selected. Emphasis is placed on the use of convolutional neural networks (CNN) with transfer learning and Data Augmentation as promising techniques to improve the accuracy and efficiency of the image interpretation process. The results show that the use of AI and DL can offer an effective alternative for the early diagnosis of lung cancer, with high sensitivity and specificity. However, current limitations and challenges that must be addressed to guarantee its responsible and safe application in clinical practice are also identified, such as the lack of standardized data, the ex plainability of the models, patient privacy, and the ethical and social implications. It is concluded that the use of AI and DL can have a positive impact on the care of patients with lung cancer, but further research and regulation are required to ensure its quality and reliability.

Lung cancer remains the leading cause of cancer-related mortality worldwide, while histopathological diagnosis is often affected by inter-observer variability and the substantial workload associated with manual slide examination. Although deep learning has shown considerable potential in computational pathology, comprehensive benchmarks that integrate tissue classification and region segmentation within a unified analytical framework remain limited. This study presents a two-stage deep learning framework for multi-class tissue classification and pixel-level histopathological region segmentation, accompanied by a systematic comparison of state-of-the-art architectures at each stage. For tissue classification, six models, a custom convolutional neural network, VGG16, DenseNet, MobileNetV3, a custom Vision Transformer, and YOLO11, are evaluated on a combined dataset of 39,000 images derived from LC25000 and LungHist700. The models distinguish between adenocarcinoma, squamous cell carcinoma, and normal lung tissue. YOLO11 achieves the best classification performance, with an accuracy of 98.38%, a five-fold cross-validation accuracy of 98.21 +/- 0.35%, and a macro F1-score of 0.98. For region segmentation, U-Net, ResNet-encoder U-Net, DeepLabV3+, and YOLO11-seg are evaluated using the GlaS gland segmentation benchmark. DeepLabV3+ obtains the highest Intersection over Union of 0.80 and a Dice score of 0.89, while YOLO11-seg achieves a comparable Intersection over Union of 0.79 using approximately 14x fewer parameters. The best-performing classification and segmentation models are subsequently integrated into an end-to-end framework, providing an accurate, computationally efficient, and reproducible baseline for automated histopathological image analysis.

Lung cancer is the leading cause of cancer-related mortality, with approximately 2.5 million new cases and 1.8 million deaths annually, making reliable diagnosis a clinical priority. Although deep learning models have achieved strong performance in lung cancer classification, evaluation has largely focused on predictive accuracy, leaving their decision-making processes insufficiently examined. This study compares three architecturally distinct models: a Convolutional Neural Network (CNN), a pretrained ResNet50, and a Vision Transformer (ViT), trained on the IQ-OTH/NCCD lung cancer CT dataset. Local Interpretable Model-Agnostic Explanations (LIME) were applied to investigate model reasoning. In addition to standard performance metrics, a dual-correlation framework was introduced to measure both prediction agreement and explanation agreement across model pairs. All three models achieved strong classification performance, with ResNet50 attaining 98.61% accuracy, CNN 97.91%, and ViT 93.75%, while all achieved ROC-AUC scores of 0.99. Prediction correlations exceeded 0.99 across all model pairs, indicating highly consistent outputs. However, LIME explanation correlations remained below 0.26, revealing substantial differences in the image regions used to reach those predictions. Analysis of misclassified samples further identified a consistent spatial pattern: incorrect predictions were associated with attention outside the lung parenchyma, whereas correct predictions focused primarily within lung regions. These findings demonstrate that prediction agreement is a poor proxy for reasoning consistency, and that interpretability evaluation must be treated as an independent validation criterion alongside predictive performance in clinical AI systems.